Aktiesnakken — Juni 2013
-
Zealand Pharma (Buy)
In only 11 weeks, Sanofi has managed to grab 8.1 percent of the market (by volume) in Germany – in our view a very impressive achievement, which could make our 10 percent peak market share estimate (value) overly conservative. Lixi/Lantus combination to start Phase 3 in H1 14; in line with our expectations. We maintain our Buy recommendation and DKK100 target price."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind